Servier's $1.5B bet on Edgewise drug fails five months in

EndpointsView source article

Part of story

Servier's $1.55 billion muscular dystrophy drug fails pivotal trial

Servier's sevasemten, acquired from Edgewise for $1.55 billion upfront in June 2026, failed its pivotal trial for muscular dystrophy just five months after the acquisition.

Nov 3, 20262 sourcesClinical trials Mergers and acquisitions Pharmaceutical Industry Rare diseases Mergers & acquisitions (M&A)Drug development Genetic diseases

Servier's $1.55 billion muscular dystrophy drug fails pivotal trial

Other sources for this story

STAT News

Servier's $1.5B bet on Edgewise drug fails five months in

Part of story

Servier's $1.55 billion muscular dystrophy drug fails pivotal trial

Other sources for this story

Servier’s $1.55 billion muscular dystrophy drug fails first major test

Servier's $1.5B bet on Edgewise drug fails five months in

Part of story

Servier's $1.55 billion muscular dystrophy drug fails pivotal trial

Other sources for this story

Servier’s $1.55 billion muscular dystrophy drug fails first major test